Dualitas Therapeutics announced a $65 million Series A financing to advance its bispecific antibody platform targeting immune and inflammatory diseases. The company’s technology leverages proximity biology to simultaneously engage two targets on the same immune cell, aiming to achieve therapeutic benefits beyond monoclonal antibodies. Investors include Eli Lilly and Chugai Pharmaceutical. This funding positions Dualitas to accelerate discovery and development of novel immunomodulatory agents.